CX3CL1 and myasthenia gravis: Briefly, iPSCs were first differentiated into CD43 + hematopoietic stem cells (CD 43 + HPCs) (Additional file 1: Fig. S1), followed by treatment with IL-34, TGF-β1, and M-CSF to generate iPSC-MG precursors, and subsequently a final maturation step with CD200 and CX3CL1-stimulation to produce iPSC-MG.